MitrAssist Medical Ltd. Announces ISO Certification for Developing its Implantable Heart Valve Prostheses
MISGAV, Israel, June 4, 2012 /PRNewswire/ –
MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart
disease, announced today that it received ISO 13485:2003 Certification for the design and
development of implantable heart valve prostheses.
Today’s standard treatment for mitral valve regurgitation (MR), blood leakage or
backflow into the atrium, is open heart surgery. MitrAssist’s unique design preserves the
ventricular dynamic mode of function and mechanism, known to be crucial for long term
patient outcome. MitrAssist’s mitral valve prosthesis is delivered with a minimally
invasive procedure via a small-diameter catheter, keeping the existing valve intact. With
its unique design focused on natural mitral valve anatomy, the MitrAssist mitral valve
prosthesis will enable faster transition to minimally invasive procedures for mitral
“This is yet another small step for us moving forward towards developing a viable and
effective solution to Mitral Valve Insufficiency, following our successful completion of
the chronic animal study POC,” said Gil Naor, MitrAssist founder and CEO.
About MitrAssist Ltd.
MitrAssist Ltd. was founded in 2009 by Gil Naor, a recognized innovator in developing
medical devices, including a number of devices for cardiology. The company is a portfolio
company of The Trendlines Group’s Misgav Venture Accelerator. MitrAssist Ltd. develops
minimally invasive products for treating heart valve disease. The Company’s first product
is a percutaneous mitral valve prosthesis for treatment of MR.
The Trendlines Group (http://www.trendlines.com) establishes, invests in, and
develops innovation-based businesses in the medical and agritech fields. Seed-stage
investors, Trendlines invests principally through a platform of Israeli
government-licensed business accelerators, Misgav Venture Accelerator (
http://www.misgav-venture.com) and Mofet Venture Accelerator (
http://www.mofet-venture.com). Over the last four years, Trendlines has attracted
investments exceeding 140 million$.
Media relations: Dorit Orly +972-52-2525167 Ofir Shpigel's Media and Public Relations +972-4-9535030
SOURCE MitrAssist Medical Ltd